Epilepsy Therapy Project invests in ICVrx; Particle Sciences, Celanese to team on drug eluting devices;

> Epilepsy Therapy Project, a nonprofit group whose mission is to help accelerate new therapies for people living with epilepsy, has invested an undisclosed amount in ICVrx, a company developing therapies for central nervous system disorders. The investment will help ICVrx develop a pump to deliver anti-epilepsy drugs. Release

> Drug delivery company CIMA Labs in Brooklyn Park, MN, will now be run by Israeli firm Teva Pharmaceutical Industries as part of Teva's acquisition of CIMA parent company Cephalon. Cephalon had acquired CIMA Labs in 2004. Story

> Particle Sciences and Celanese EVA Performance Polymers are getting together to streamline development of drug eluting devices. Particle Sciences release

> The problem of multidrug resistance can possibly be solved through the use of multifunctional nanocarriers for drug delivery. Abstract

> LyoGo, a company that specializes in developing devices to deliver injected freeze-dried drugs, diagnostics and vaccines has become a tenant in the Purdue Research Park. LyoGo release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.